Supporting Decisions in Cancer
NEW Marker for Early Cancer Detection & Monitoring
The most common question asked by every patient with a serious chronic disease:
"Is my Treatment Working"?
Answering that question with accuracy and confidence is one of the most complex challenges clinicians face.
QuickLab Corporation provides the only source for quantitative ENOX2 ELISA testing world-wide, helping physicians answer critical-path questions quickly and cost-effectively. The ENOX2 marker promotes trend analysis and timely decision-making insights for implementing mid-course therapeutic modifications unlike anything available before. Furthermore, the ENOX2 test for establishing a baseline during routine examinations.
These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.